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Summary
Objective: To test the hypothesis that tenidap has a structure-modifying effect in human knee osteoarthritis.
Design: Study: multicenter, prospective, randomized, double blind, 1 year duration.
Patients: primary painful knee osteoarthritis (ACR criteria) of the medial tibiofemoral compartment, medial joint space width ≥2 mm, at least
10% of one cartilage surface of the medial compartment affected by superficial fibrillation or worse at baseline arthroscopy.
Study medication: once daily dosage of either tenidap 40 mg, tenidap 120 mg or piroxicam 20 mg.
Study endpoints: bilateral extended weight-bearing X-rays and knee arthroscopy under local anaesthesia were done at entry and after 1
year. Joint space width was measured in millimeters at the narrowest point of the medial compartment. Chondropathy was scored by using
reader’s overall assessment (VAS score, 100 mm) and Socie´te´ Franc¸aise d’Arthroscopie (SFA) score (0–100).
Results: Patients (665) were randomized and 494 completed the study. After 1 year, intra-group radiological changes and radiological
difference between both tenidap groups and the piroxicam group did not reach statistical significance. The intra-group arthroscopic
deterioration of chondropathy was low, but statistically significant in the three study groups. However, there was no statistically significant
difference between both tenidap groups and the piroxicam group.
Conclusions: This study failed to demonstrate any difference between the treatment arms with regard to the structural progression of medial
knee osteoarthritis as measured by radiography and arthroscopy. Arthroscopy did, however, appears to be more sensitive in detecting
disease progression than the weight-bearing radiographs with fully extended knees. This study shows that it is possible to complete a large
international trial using arthroscopy as an outcome measure of articular cartilage.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Introduction
Osteoarthritis (OA) greatly contributes to the overall dis-
ability in the community1, with knee OA being the greatest
contributor. The pain and gradual loss of joint function
characteristic of OA are associated with progressive loss
of articular cartilage, formation of osteophytes and joint
remodeling. However, OA is no longer considered a ‘de-
generative’ or ‘wear and tear’ disease, but it is now
recognized to involve dynamic biological and biochemical
processes. Cytokines such as interleukin-1 (IL-1), tumor
necrosis factor alpha (TNFα) and interleukin-6 (IL-6)
are thought to play an important role in the pathologic
processes2.
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Drugs considered to be active in the treatment of OA may
be classified as symptomatic and/or structure-modifying
agents3,4. The term, structure-modifying OA drugs
(SMOADs)3 is used to describe an agent that arrests or
retards the progression of OA and/or enhances normal
reparative processes in the diseased joint. Although sev-
eral agents are currently being evaluated for SMOAD
properties, none has yet been identified as an effective
SMOAD in humans.
Various methods have been proposed to measure struc-
tural changes in OA, such as plain radiographs, magnetic
resonance and arthroscopy. Radiological assessment of
joint space width on plain radiographs remains the best
non-invasive method available for assessing cartilage de-
terioration in OA5–9. However, sources of variability in joint
space width measurement are numerous, and standardiz-
ation of radiographic techniques and joint positioning is
essential to permit detection of changes over time. Longi-
tudinal studies of medial tibiofemoral OA yields annual
rates of joint space narrowing varying from 0.06 to
0.60 mm/year10. MRI is a promising technique11–14, but
evaluation of its sensitivity to change and comparison with
plain radiographs and arthroscopy require further studies.
Arthroscopy allows assessment of cartilage by direct and
magnified visualization and provides information on other
component of the joint, such as synovium and menisci.
Thus, along with the use of arthroscopy as a diagnostic or
therapeutic procedure in knee disorders, another function
of knee arthroscopy, performed under local anesthesia on
an outpatient basis, has been proposed—the monitoring
and follow-up of knee chondropathy conducted for re-
search purposes on patients suffering from knee OA15,16.
The development of this arthroscopic outcome measure-
ment of chondropathy has become possible with the es-
tablishment and validation of scoring systems17–21.
Arthroscopy was found to be more sensitive than X-rays or
MRI for detecting cartilage abnormalities22. Arthroscopy
has also been shown to be sensitive to change, i.e., to be
capable of detecting a statistically significant worsening of
cartilage over a 1 year period in medial knee OA15.
Analgesics and non-steroidal anti-inflammatory drugs
(NSAIDs) are widely used to control pain associated with
OA. Neither treatment modality has been shown to reduce
the rate of progression of OA in humans23. Tenidap, an
oxindole derivative, has been studied in patients with
rheumatoid arthritis and OA. Tenidap inhibits cyclo-
oxygenase activity and also cytokine production24,25. This
suggests that it could have dual activity in OA, both as a
disease modifier and as an NSAID. In in vitro studies,
tenidap increases the rate of synthesis of glycosaminogly-
cans26,27, inhibits IL-1R and reduces collagenase and
stromelysin synthesis in OA28. In animals studies, tenidap
protects cartilage from IL-1-induced cartilage degradation,
down-regulates the IL-1 receptor and inhibits IL-1-
stimulated metalloproteinase synthesis in chondrocytes
derived from normal and OA human cartilage29,30. In
canine experimental OA, tenidap has produced effects
suggesting that it can slow down the progress of OA29,30. In
the mongrel dog model, in which OA-like changes are
produced by anterior cruciate ligament section, tenidap, but
not diclofenac, given prophylactically produced dramatic
beneficial effects on cartilage integrity, osteophyte for-
mation, metalloproteinase levels and synovial inflam-
mation29. The effect of tenidap on macroscopic lesions of
OA and on metalloprotease activity in this dog model
seems dose-dependent with the greater effect obtained
with the higher dose31. Animal data suggest that 40 mg
tenidap daily may be an adequate dose to slow down the
OA progression in humans, but because of the different
pharmacokinetics in animals, it is difficult to accurately
extrapolate to human. A disease-modifying effect of tenidap
was found in two other animal studies, in the post-contusive
chondropathy of the patella of the rabbit32 and in male
STR/ORT mice with naturally occurring knee OA33. In this
latter study, tenidap modified OA development when it was
given prophylactically, and also modified progression of
established disease (‘curative’ effect).
Large clinical studies in humans have shown that tenidap
is equivalent to an NSAID for control of OA symptoms.
These studies were not designed to study structural pro-
gression of OA. In rheumatoid arthritis, one multicenter,
double blind study comparing tenidap 120 mg, piroxicam
20 mg and piroxicam with hydroxychloroquine 400 mg/day,
showed a significantly reduced rate of X-ray deterioration of
hands and wrists in the tenidap group compared to the
piroxicam group at 24 and 52 weeks, suggesting a disease-
modifying effect of tenidap in arthritis34. The NSAID com-
parator was piroxicam because it is a very widely used
NSAID, which provides good symptom control35 and ap-
pears to be free from the harmful effects on cartilage26,36.
The present prospective longitudinal study was con-
ducted in patients with painful knee OA of the medial
tibiofemoral compartment. It aimed to compare the struc-
tural effects of tenidap 40 mg, tenidap 120 mg and piroxi-
cam 20 mg using arthroscopy as the primary endpoint, and
radiology as a secondary endpoint.
Methods
PATIENTS
Inclusion criteria were as follows: patients with clinical
involvement of the medial tibiofemoral compartment of the
knee (pain localized at the medial part of the knee) and
satisfying the American College of Rheumatology criteria
for knee OA37—pain in the signal knee and either A or all
the items under B (A: tibiofemoral osteophytes present on
knee X-ray, B: (i) morning stiffness if present lasts less than
30 min, (ii) crepitus present on active motion, and (iii)
synovial fluid collected in the last year with at least two of
the following features: clear, viscous, white blood cell count
<2000/ml). Other criteria for eligibility were: (1) age, 45–75
years, (2) body mass index (BMI), 25–50, (3) active dis-
ease defined by pain of any duration in the signal knee on
at least 30 days in the last 2 months, and which might
benefit from joint lavage, (4) ambulatory patient, (5) radio-
logical joint space of 2 mm or greater at the narrowest point
of the medial compartment of the signal joint on weight-
bearing radiographs with knee fully extended, (6) no lesion
requiring surgery (e.g., of meniscus, cartilage or ligament)
at screening arthroscopy, or likely to require surgery during
the study period, and (7) presence of chondropathy of the
medial compartment at entry, approved by central reader of
video made during screening arthroscopy; for approval, at
least 10% of one articular surface of the medial compart-
ment (femoral condyle or tibial plateau) had to be affected
by superficial fibrillation or worse; if 90% or greater of both
surfaces showed absence of cartilage, the patient was not
eligible.
Exclusion criteria were the following: (1) knee OA sec-
ondary to other bone or joint disease, (2) initial diagnosis of
knee OA (either knee) made by a physician more than 10
years before, (3) any of the following procedures prior to
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the screening arthroscopy: injury to joint and arthroscopy
within 2 months prior to entry, intra-articular injection within
3 months, intra-articular surgery including meniscal trim-
ming within 2 years, osteotomy within 3 years, (4) any
chronic inflammatory joint disease, including rheumatoid,
ankylosing spondylitis and crystal arthropathies, and (5)
treatment with corticosteroids (oral, intravenous, intra-
muscular) in last 3 months, previous tenidap treatment in
last 4 months and piroxicam within 1 month.
STUDY DESIGN
This longitudinal, prospective, multicenter study of 1 year
duration involved 45 centers in Australia, Belgium, Canada,
Denmark, Finland, France, Hungary, Norway, Spain, United
Kingdom and U.S.A. The study was conducted according
to the Declaration of Helsinki (Revised Hong Kong 1989)
and received ethics approval at each center. Each patient
gave written, informed consent prior to recruitment. A
weight-bearing X-ray of each knee and an arthroscopy of
the signal joint were performed at screening and study
completion. Arthroscopy videotapes (primary endpoint)
were sent to the central reader (XA, Cochin, Paris) for
quality control and assessment of the arthroscopic inclu-
sion criteria. There was no ongoing quality control for
X-rays (secondary endpoint). After satisfaction of all entry
criteria, patients were randomized equally to one of three
study groups (tenidap 40 mg, tenidap 120 mg, piroxicam
20 mg). Rescue treatment by paracetamol was dispensed
as required.
DATA COLLECTION
At baseline
The following characteristics were noted: demographic
data including age, sex, body mass index, disease
duration.
At baseline and at 12 months
Symptomatic severity of OA. Symptomatic severity of
OA was also assessed during the study, before arthros-
copy, using the following variables: WOMAC global and its
three subscales: pain, stiffness, physical function that was
measured using a five-point Likert scale (none, mild, mod-
erate, severe, extreme)38, patient and physician assess-
ment of global status was measured using a five-point
Likert scale. A re-scaling was used to permit the presen-
tation of the results in a 0–100 scale in which ‘0’ indicates
no impairment and ‘100’, extreme impairment.
Radiological variables. Radiological evaluation con-
sisted of bilateral anteroposterior weight-bearing knee
radiographs with the knees fully extended. Paired radio-
graphs were taken in the same radiography unit in each
arthroscopy center using a standardized technique39: (i)
patient positioning: patients stand with knees fully ex-
tended, weight equally distributed on both legs, back of
knees in contact with the film cassette, feet rotated so that
tibial spines are centralized in femoral notch; paper is
placed under feet at screening X-ray and outline of feet are
drawn; the feet are placed in the same position on the
paper for the second X-ray, (ii) radiographic procedure:
both knees are X-rayed together, X-ray beam directed
at center of medial compartment of signal knee, using
fluoroscopy where available, beam parallel to medial tibial
plateau; radiographer notes X-ray beam angle and tube to
film distance.
For the second X-ray at 12 months there was attempt to
reproduce technique of first X-ray, by ensuring that feet are
identically positioned on the feet drawing and by using
same beam angle and same tube to film distance. The
severity of OA of the medial tibiofemoral compartment was
evaluated by a single investigator using Kellgren and
Lawrence grading40, and by measuring the joint space
width in millimeters at the narrowest point of the medial
compartment by using a 0.1 mm graduated magnifying
glass (10× magnification).
Arthroscopy. Arthroscopy of the knee was performed
under local anesthesia, without tourniquet homeostasis,
with a standard knee arthroscope or with a smaller glass
lens arthroscope (2.7 mm), having both a 30° fore oblique
lens and a wide field of view, using the infero lateral
approach. In most sites, the same size of arthroscope was
used at entry and after 12 months. Arthroscopic exploration
was combined with joint lavage, with a volume of 1 l of
normal saline. Only the exploration of the medial compart-
ment was recorded on a VHS videotape (Sony, Tokyo,
Japan). Video recording of articular cartilage surface of the
femoral condyle and tibial plateau was standardized as
previously reported21. Almost all centers had only one
arthroscopist who performed all procedures. Prior to
screening their first patient, a center had to provide
videotape to the central reader (XA) demonstrating suc-
cessful use of the required technique. During the study, all
screening videotapes were sent to the central reader for
confirmation of eligibility and for feedback to the arthro-
scopist. Such a procedure was not done for the X-rays.
For the evaluation of medial tibiofemoral chondropathy
three scoring methods were used: the overall assessment
of the investigator17, the Socie´te´ Franc¸aise d’Arthroscopie
(SFA) scoring system and the SFA grading system18,19.
The overall assessment of chondropathy uses a 100 mm
VAS in which ‘0’ indicates the absence of chondropathy and
‘100’, the most severe chondropathy. One VAS is used for
each articular surface, i.e., medial femoral condyle and
medial tibial plateau. A VAS score is calculated for the
medial tibiofemoral compartment by averaging the VAS
scores from the medial condyle and plateau.
In the SFA systems for scoring and grading chondropa-
thy, the first step consists of reporting on an articular
diagram of the knee the observed chondropathy with three
main baseline variables: (1) location: medial femur and
medial tibia, (2) depth based on the classification of chon-
dropathy proposed by Beguin and Locker41 in which grade
0 indicates normal cartilage, grade I, swelling and/or
softening, grade II, superficial fibrillations, grade III, deep
fibrillations down to bone, and grade IV, exposure of
subchondral bone, and (3) extent from 0 to 100% of the
involved articular surface. Extent of lesions is estimated by
the investigator as a percentage of the whole articular
surface and is reported on a special form.
The composite indices of severity of chondropathy taking
into account location, depth, and extent of cartilage lesions
are:
• The SFA score, which is a continuous variable, be-
tween 0 and 100, and obtained as follows19:
SFA scoreextent (%) of grade I lesions0.14
extent (%) of grade II lesions0.34
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extent (%) of grade III lesions0.65
extent (%) of grade IV lesions1.00.
For each compartment, the extent (%) of grade 0 to 4
corresponds to the mean value of the extent of the
grade of the two articular surfaces of the compartment,
i.e., medial femoral condyle and tibial plateau in the
present study.
• The SFA grade (or category of chondropathy severity of
the compartment) is a semiquantitative variable includ-
ing five categories for the femorotibial compartments18.
STUDY SCHEDULE
Assessment of clinical activity, radiological and arthro-
scopic evaluations were performed at entry and after 1 year
of follow-up.
Changes in clinical activity were assessed in each ar-
throscopy center by an unblinded investigator unaware of
the results of the serial arthroscopies, as the assessment of
clinical activity was performed before the arthroscopic
evaluation. The paired radiographs of each patient at entry
and after 1 year were analyzed by one investigator (HKG),
using a blind procedure in which the investigator was
unaware of patient identity, study treatment and chronology
of the radiographs. The paired arthroscopy videotapes of
each patient at entry and after 1 year were analyzed by one
investigator (XA) using a blind procedure in which the
investigator was unaware of patient identity, study treat-
ment and the chronology of the arthroscopy videotapes.
STATISTICAL ANALYSIS
Justification of study numbers
A sample size of 100 completing patients per group was
considered to be adequate to be able to detect a 50%
difference between treatments in the change from baseline
in SFA scoring of arthroscopic evaluation. These calcu-
lations assumed a power of 90% (at the 5% level of
significance), a standard deviation of 9.5 and a difference
to detect of 4.5. These figures are based on a previous
study in which patients received no treatment15. It was
assumed that patients receiving piroxicam for a year would
show similar changes to placebo.
The primary efficacy variables for this study were the
arthroscopic parameters: VAS score and the SFA scoring
and grading systems. Secondary efficacy measures in-
cluded X-ray scores, WOMAC indices, patient and phys-
ician global assessment of the disease and the proportion
of patients discontinuing due to lack of efficacy.
Statistical analyses were performed to compare, by treat-
ment groups, the changes, which occurred in the clinical,
radiological and arthroscopic variables after 1 year follow-
up. For the continuous efficacy variables, the Student’s
paired t test (two-tailed) was used for intra-group compari-
son, and the analysis of covariance (ANCOVA) using the
corresponding baseline assessment as the covariate was
performed for intergroup comparison; categorical variables
were analyzed by chi-square test.
Results
PATIENTS CHARACTERISTICS
From November, 9, 1995 to June, 10, 1996, 665 subjects
were randomized and received study medication, of whom
494 (74%) completed the study. Twelve subjects (1.8%)
were lost to follow-up. Roughly equal numbers of subjects
were randomized to each of the three treatments groups.
The final disposition of the 665 randomized subjects is
summarized in Table I and their baseline characteristics
are summarized in Table II. There appears to be no
major imbalance of these attributes between treatment
groups.
EFFICACY
Clinical parameters
Within all three of the treatment groups, there was a
statistically significant improvement in the WOMAC and
physician/patient global assessments after 1 year follow-up
(Table III). The differences between treatment groups were,
however, not statistically significant (Table III). The propor-
tion of patients discontinuing due to lack of efficacy was the
same in the three treatment groups (Table I).
Structural parameters
The changes in severity of chondropathy evaluated by
both X-rays and arthroscopy are summarized in Table IV.
The average loss of radiological joint space width in both
tenidap groups was 0.0 mm/year, numerically less than that
in the piroxicam group (−0.1 mm/year), but the differences
did not reach statistical significance.
The arthroscopic rate of deterioration of chondropathy
assessed by the VAS score was 3.0–3.5 mm/year and the
rate of deterioration in SFA score was from 1.7 to 2.0 units/
year in the study groups; these intra-group changes were
statistically significant (Table IV). However, there was no
statistically significant differences between treatment
groups for the VAS and SFA scores (Table IV) and for the
SFA grade (data not shown).
Treatment effect, estimated by the standardized re-
sponse mean, is summarized in Table V. No intergroup
difference was found for each radiological and arthroscopic
variable in terms of structural effect. However, arthroscopy
was more sensitive to change than plain radiographs based
on the results of the standardized response mean of the
two technics (Table V).
SAFETY
Drugs
A total of 1557 adverse events were reported during the
study and 90 patients (14%) did not complete the study
because of adverse events. There was no noticeable
difference in the number of patients experiencing adverse
events in the three treatments groups (data not shown).
Arthroscopy
Complications from arthroscopy were unusual and minor,
except for one patient who developed septic arthritis after
the screening arthroscopy. He was hospitalized for intra-
venous antibiotics and ultimately recovered, but was not
randomized into the trial.
Discussion
This double-blind, randomized, controlled study failed
to demonstrate any difference between tenidap 40 mg,
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tenidap 120 mg and piroxicam 20 mg with regard to the
structural progression of medial knee OA after 1 year
follow-up assessed by arthroscopy and X-rays.
Based on animal data, tenidap 40 mg daily was pro-
posed as an adequate dose to slow down OA in humans.
However, tenidap 120 mg was also tested for structure-
modifying effect. It was thought that it would be difficult to
keep patients on placebo for a year and therefore an
NSAID comparator was used. Piroxicam was selected
because it was thought not to affect cartilage. All three
treatments were subjected to joint lavage at baseline.
Lavage was performed in all patients on the basis that
it might give symptomatic benefit to at least some
patients42,43.
The rate of disease progression in this study was low for
both arthroscopy and radiology endpoints. This was
Table I
Trial profile
Table II
Characteristics of the 665 randomized patients
Variable Treatment group
Tenidap 40 mg (n224) Tenidap 120 mg (n220) Piroxicam 20 mg (n221)
Demographic data
Age (years) 62 (45–76)* 61 (45–76) 61 (45–75)
Sex (female/male) 137/87 134/86 135/86
BMI 30 (23–45) 30 (24–47) 31 (23–50)
Disease duration (years) 3.7 (0.0–10.0) 3.6 (0.0–20.0) 3.4 (0.0–11.0)
Clinical activity
WOMAC global score (0–100) 40 (5–100) 43 (0–85) 43 (5–88)
Radiological severity
Kellgren and Lawrence score† 203 204 205
0 10 3 11
I 21 29 20
II 112 107 123
III 48 57 48
IV 12 8 3
Arthroscopic severity
Chondropathy—overall assessment (100 mm VAS) 40 (6–85) 39 (2–87) 38 (8–92)
Chondropathy—SFA score (0–100) 33 (3–90) 32 (1–86) 30 (2–76)
*Values are mean value (range).
†Data were missing for 21, 16 and 16 patients for tenidap 40 mg, tenidap 120 mg, and piroxicam 20 mg, respectively.
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despite the inclusion of relatively obese patients with pain-
ful OA. This was expected to result in a population that was
likely to show disease progression4 and in whom it would
be easier to detect the benefit of a structure-modifying
effect. In a previous arthroscopy and radiology study of
similar design in 41 patients15, the mean changes±
standard deviation after 1 year were 10±16, 6±10, −0.4±1.0
for the VAS score, the SFA score and the joint space width,
respectively; all these changes were statistically significant.
In the present study, the progression of medial chon-
dropathy as assessed by arthroscopy was lower in all
treatment groups, but still statistically significant, confirming
the sensitivity to change of arthroscopy as an outcome
measure of chondropathy. At variance, radiographic
changes were not statistically significant. The standardized
response mean of radiologic and arthroscopic changes
confirmed the higher sensitivity to change of arthroscopy
over weight-bearing X-rays in extended position. This
finding might have different explanations.
In this study we proposed, as secondary endpoint, meas-
urement of medial joint space width on weight-bearing
radiographs in anteroposterior view using fluoroscopy. This
choice was based on the OA Research Society (OARS)
guidelines for clinical trials in OA4. They proposed, during
the period of the study, two radiographic views of the knee
to assess structural progression of the tibiofemoral com-
partment: the anteroposterior standing extended knee
view39,44,45 and the anteroposterior standing semiflexed
view5,46,47. Fluoroscopy is used in both views to ensure
correct radioanatomic positioning of the joint with respect to
alignment of the X-ray beam. Correction for the effect of
radiographic magnification is required in the semiflexed
view because of the joint’s distance from the radiographic
film and is obtained by attaching a metal ball to the side of
Table III
Changes in clinical variables by treatment group after 1 year follow-up
Variable Treatment group N Baseline
(mean±standard deviation)
Change after 1 year
(mean±standard deviation)*
P-value†
WOMAC pain (0–100) Tenidap 40 mg 222 38.0±18.9 −10.0±22.3 0.767
Tenidap 120 mg 212 39.2±17.0 −10.3±21.8 0.905
Piroxicam 20 mg 215 39.9±18.6 −10.5±22.0
WOMAC stiffness (0–100) Tenidap 40 mg 222 40.0±22.6 −8.8±26.0 0.890
Tenidap 120 mg 213 41.3±21.5 −9.6±25.5 0.823
Piroxicam 20 mg 216 42.1±23.7 −9.1±25.8
WOMAC function (0–100) Tenidap 40 mg 212 40.7±18.9 −9.6±21.8 0.613
Tenidap 120 mg 207 42.3±16.9 −10.3±21.5 0.376
Piroxicam 20 mg 209 42.7±17.5 −8.8±21.8
WOMAC global (0–100) Tenidap 40 mg 211 39.3±17.2 −9.3±21.8 0.571
Tenidap 120 mg 204 41.1±15.5 −10.6±21.5 0.776
Piroxicam 20 mg 207 41.8±17.5 −10.2±21.5
Patient assessment (0–100) Tenidap 40 mg 220 53.5±19.9 −7.2±22.3 0.841
Tenidap 120 mg 211 53.0±17.6 −8.8±25.5 0.531
Piroxicam 20 mg 216 54.4±18.3 −7.6±22.0
Physician assessment (0–100) Tenidap 40 mg 221 52.7±17.3 −14.7±22.3 0.898
Tenidap 120 mg 216 51.9±18.7 −15.8±22.0 0.617
Piroxicam 20 mg 219 52.2±16.7 −15.0±22.3
*P<104 for intra-group comparison (Student’s paired t test).
† Inter-group comparison: difference from piroxicam group (ANCOVA analysis).
Table IV
Changes in severity of chondropathy by treatment group after 1 year follow-up
Variable Treatment group N Baseline
(mean±standard deviation)
Change after 1 year
(mean±standard deviation)
P-value* P-value†
Radiology
Joint space width (mm) Tenidap 40 mg 153 4.0±1.5 0.0±1.6 0.9387 0.448
Tenidap 120 mg 139 3.7±1.4 0.0±1.5 0.8177 0.616
Piroxicam 20 mg 149 4.0±1.4 −0.1±1.6 0.3989
Arthroscopy
Overall assessment
(100 mm VAS)
Tenidap 40 mg 178 39.8±18.8 3.2±10.5 0.0001 0.769
Tenidap 120 mg 156 39.1±17.7 3.0±10.2 0.0003 0.633
Piroxicam 20 mg 170 37.4±17.3 3.5±10.4 0.0000
SFA score (0–100) Tenidap 40 mg 178 36.6±20.5 2.0±7.6 0.0007 0.783
Tenidap 120 mg 156 36.1±19.7 1.7±7.4 0.0053 0.877
Piroxicam 20 mg 170 33.3±18.3 1.8±7.6 0.0025
*Intra-group comparison (Student’s paired t test).
† Inter-group comparison: difference from piroxicam group (ANCOVA analysis).
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the knee. In this study, fluoroscopy was used at most sites
in order to control the X-ray beam position, but in a small
number of sites, fluoroscopy was not available. Because it
was a secondary endpoint, there was less focus on the
monitoring and quality control of the X-rays than there
was for the arthroscopic technique. Therefore, this study
does not allow a definitive comparison of the benefits of
arthroscopy vs X-rays.
In 1999, a new radiographic view was proposed by
Buckland-Wright et al.7, the posteroanterior standing
semiflexed view, also called ‘MTP view’, which does not
require correction in the absence of magnification (knees in
contact with the film cassette). In the absence of fluoro-
scopic control, it appears that the posteroanterior semi-
flexed view provides more accurate radioanatomic joint
positioning and more reproducible joint repositioning and
JSW measurement, than the anteroposterior extended
view and the posteroanterior flexed view with the knees in
the ‘schuss’ position (or ‘tunnel’ position)7. However, in
1995, at the time of beginning the present study, the ‘MTP
view’ was not available. Moreover, its sensitivity to change
remains to be evaluated.
It could also be argued that digitized assessment of joint
space width or automated joint space measurement of
digitized radiographs was not employed and could have
improved the quality of measurement and the sensitivity to
change of plain radiographs. In 1996, Ravaud et al.45 found
that digitized assessment had better reliability than meas-
urement with a graduated magnifying glass; however, the
intra-observer reliability of this latter technique was also
excellent. Automated joint space measurement could not
be used in the present study, that ended in 1996, since
publication dates from 20009.
The better sensitivity to change of arthroscopy could be
explained by its precision, since it provides a direct and
magnified visualization of cartilage lesions. One major
advantage of arthroscopy is to permit a complete evalu-
ation of the articular surfaces, especially the posterior
weight-bearing part of the medial compartment where
cartilage deterioration starts and increases. This crucial
area of tibiofemoral OA cannot be evaluated by radio-
graphs with knees fully extended. At variance, the postero-
anterior flexed view (‘schuss’ or ‘tunnel’ view) is capable of
detecting early joint space narrowing that is unknown on the
extended view48,49. The posteroanterior semiflexed view
should also improve the diagnosis of early OA despite a
lower degree of flexion. Comparison of disease progression
assessed by arthroscopy and standing radiographs with
knees in posteroanterior flexed or semiflexed position
would be of great interest.
It could be argued that arthroscopy changes in this
study are ‘false positive’, not related to the sensitivity to
change, but to the ‘noise’ of the technique. Ravaud et al.
have published the definition of cutoffs for the assess-
ment of progression of a group of patients50. According
to this definition and to the intra-observer reproducibility
of the arthroscopy central reader (XA)15, it can be stated
that in the present study dealing with 494 patients, a
change of more than 0.34 and more than 0.20 for the
VAS score and the SFA score, respectively, is related to
disease progression and not to the noise of the technique.
Thus, changes of chondropathy assessed by arthros-
copy in this study correspond to a low but real disease
progression.
In a preliminary monocenter, prospective, randomized
study of 1 year duration (36 completers), comparing re-
peated hyaluronic acid injections vs no injections, arthros-
copy was found to be discriminant, i.e., to be capable of
identifying disease-modifying effect of hyaluronic acid51. In
the present study, no intergroup difference was seen in the
progression of chondropathy, and a structure-modifying ef-
fect of tenidap was not confirmed. The low rate of disease
progression in this study was especially surprising given that
only patients with risk factors for rapid progression were
included in the study, i.e., painful OA with BMI≥25. Patients
were required to have at entry joint space width of 2 mm or
more; again, the intent was to ensure that there was suf-
ficient cartilage present for further disease progression
to occur. Approximately a quarter of the patients in each
treatment group did not complete the study, but the
characteristics of these non-completers do not appear
to differ between treatment groups, and we have no evi-
dence to suggest that these dropouts were more rapid
progressors than the patients who completed the study.
Based on literature review, the assumption during study
design was that the lavage, which is integral part of arthros-
copy, would not affect disease progression. We cannot ex-
clude the possibility that some aspect of the baseline
arthroscopic lavage was the cause of the relatively slow
disease progression over the ensuing year. However, we still
think that this is unlikely, given the more rapid progression
of chondropathy in a previous smaller arthroscopy study of
similar design15.
Could 20 mg piroxicam daily for 1 year have a chondro-
protective effect and interfere with the interpretation of
tenidap results? Piroxicam is categorized into the class of
NSAIDs that are neutral of glycosaminoglycan synthesis in
chondrocytes, e.g., with no action on cartilage matrix26,36.
Thus, piroxicam was logically considered in this study as a
placebo with regard to structure-modifying effect. However,
NSAIDs might have an influence on cartilage matrix by
interacting with synovial synthesis of catabolic factors such
as TNFα, IL-1, IL-6. One in vitro study has suggested
that piroxicam might have SMOAD activity in this way52.
Herman et al. found that when OA synovial membrane
Table V
Treatment effect on radiological and arthroscopic severity of chon-
dropathy after 1 year follow-up
Variable Treatment
group
Standardized
response
mean*
Radiology
Joint space width (mm) Tenidap
40 mg
0.006
Tenidap
120 mg
0.020
Piroxicam
20 mg
0.069
Arthroscopy
Overall assessment (100 mm VAS) Tenidap
40 mg
0.306
Tenidap
120 mg
0.297
Piroxicam
20 mg
0.336
SFA score (0–100) Tenidap
40 mg
0.258
Tenidap
120 mg
0.227
Piroxicam
20 mg
0.235
*Mean within group change divided by its standard deviation.
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explants were cultured in the presence of clinically relevant
concentrations of piroxicam, synthesis of factors, which
stimulated catabolism of cartilage was suppressed52.
This effect was not found with sodium salicylate nor with
indomethacin. Thus, it could be imagined that long-term
treatment by piroxicam might slow structural progression of
painful knee OA, but this potential structure-modifying
effect of piroxicam has never been evaluated against
placebo in human knee OA.
The last hypothesis to explain the absence of structural
effect of tenidap in the present study would be that tenidap
has effectively no structural effect in primary knee OA in
human, when used as ‘curative’ therapy. This situation is
actually quite different from its evaluation as a ‘preventive’
treatment in secondary OA in dog model29 or in post-
contusive chondropathy32.
Clinical results confirm that tenidap 40 mg efficacy is
equivalent to recommended dose of piroxicam (20 mg).
Greater dose of tenidap (120 mg) does not result in greater
clinical efficacy. In the same way, greater dose of tenidap
(120 mg) does not result in significative greater rate of
adverse events. Frequency of severe side effects was the
same in the three treatment groups.
The results of this study did not show a clear structural
benefit with tenidap, and the development of this drug was
subsequently discontinued because trials did not show
convincing evidence of structure modification.
This study is of interest since it is the first worldwide
study using arthroscopy as the outcome measure of articu-
lar cartilage in more than 500 patients treated with a
potential structure-modifying OA drug. This study shows
that it is possible to complete an international trial of this
nature. In particular, we showed that patients would
complete such a study including a second arthroscopy
under local anesthesia. Training and screening of
arthroscopy centers are necessary due to the performance
of arthroscopy under local anesthesia, which requires
specific training for the comfort of the patient and the quality
of the images, even for experienced arthroscopists. Such a
study requires the use of one central reader whose intra-
observer reliability of quantification of chondropathy has
been tested. As previously reported15,16,51, changes of
VAS score and SFA score are concordant. From a practical
point of view, the overall assessment of chondropathy by
using the VAS score is much more easy and rapid than the
SFA score and should be recommended for large clinical
trials. The unexpectedly low rate of disease progression in
this study is unexplained and should act as a caution to
others contemplating similar studies. Arthroscopy did,
however, appear to be more sensitive in detecting disease
progression than weight-bearing X-rays in extended
position.
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